Azora Therapeutics Quarterly Cash Flow Statement
NASDAQ: AZRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.85-0.02 (-0.52%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Azora Therapeutics free cash flow
In the quarter ended Sep 30, 2026, Azora Therapeutics generated -$6.6 million of operating cash flow. That left free cash flow of -$6.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Azora Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q2 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -64.56M | -51.99M | -2.02M | -2.00M | -1.79M | -1.96M | -2.23M | -2.07M | -2.19M | -2.46M | -6.48M | -1.92M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | -325.99% | — | — |
| Stock-Based Compensation | 958.00K | 137.10K | 147.90K | 168.20K | 147.00K | 124.27K | 236.73K | 180.20K | 188.26K | 202.38K | 225.99K | 280.85K |
| Change in Working Capital | -230.00K | -716.98K | 193.98K | 251.87K | -264.00K | 19.62K | 408.38K | 278.10K | -54.04K | 185.91K | 67.90K | 180.90K |
| Operating Cash Flow | -6.63M | -6.36M | -1.61M | -1.32M | -1.83M | -1.75M | -1.59M | -1.45M | -1.69M | -2.15M | -1.63M | -1.22M |
| Investing Cash Flow | 0 | — | — | 0 | 0 | 0 | 150.00K | — | — | — | — | 350.00K |
| Share Repurchases | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Financing Cash Flow | -35.00K | 25.21M | 315.28K | 2.60M | 525.00K | 5.30M | 50.65K | 0 | 3.61M | 411.09K | 3.82M | 3.38M |
| Net Change in Cash | -6.67M | 24.13M | -1.30M | 1.27M | -1.31M | 3.55M | -1.38M | -1.45M | 1.92M | -1.74M | 2.20M | 2.51M |
| Free Cash Flow | -6.63M | -6.36M | -1.61M | -1.32M | -1.83M | -1.75M | -1.59M | -1.45M | -1.69M | -2.15M | -1.63M | -1.22M |
This table shows 12 quarterly periods of Azora Therapeutics's cash flow statement, from Q3 2026 back to Q4 2023, across 12 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow AZR's reporting calendar. What is a cash flow statement?